Cori Clinical Raised $4 Million for AI Trial Planning

The startup aims to lower high costs associated with protocol amendments by using AI to identify errors in clinical trials.

Updated on Oct. 14, 2026 in Biotech

Isometric editorial illustration showing a glass flask filled with a glowing geometric network of nodes, representing clinical trial data analysis. — Cori Clinical raised $4 million in seed funding to scale its AI platform designed to detect errors in clinical trial protocols. AI Illustration. Upload story photo >

Live Poll

Do you trust AI platforms to improve the accuracy and speed of medical clinical trials?

Cori Clinical has announced a $4 million seed funding round led by Breega to scale its clinical and regulatory intelligence platform. The platform is currently used by two of the world's five largest clinical research organizations and Erasmus MC in the Netherlands.

Why it matters

Clinical trial protocols frequently undergo costly changes, with amendments to Phase 2 and 3 studies creating significant financial burdens. Cori Clinical aims to reduce these overheads by automating error detection before trials begin.

Internal modeling indicates the software can reduce trial set-up costs by 33%. The platform identifies 82% of avoidable protocol errors by aggregating data from trial registries and regulatory guidance.

The players

Cori Clinical

A startup building AI-driven clinical and regulatory intelligence tools for pharmaceutical and clinical research firms.

Breega

A venture capital firm focused on supporting early-stage technology companies.

Dr. Emma Ogburn

The newly appointed Chief Clinical Officer tasked with overseeing the clinical development of the platform.

Erasmus MC

A major academic medical center in the Netherlands that currently utilizes the Cori Clinical platform.

The details

The platform functions by synthesizing clinical trial experience with information parsed from regulatory guidance documents and public trial registries. By acting as an AI reviewer, the system flags potential protocol inconsistencies that often lead to later amendments. A 2026 study from the Tufts Center for the Study of Drug Development highlighted that 76% of protocols require amendments, which can cost $141,000 for Phase 2 trials and $535,000 for Phase 3 studies.

A Tufts Center for the Study of Drug Development study was published in 2026.
Cori Clinical announced its seed funding round on October 14, 2026.

The Tech Race

This development follows the precedent set by the 2026 Tufts Center for the Study of Drug Development study, which quantified the extreme financial toll of protocol amendments. Cori Clinical is racing to displace manual, reactive trial planning with proactive, AI-driven oversight.

Pharmaceutical companies and clinical research organizations are the primary users of this platform, with the technology aimed at streamlining trial set-up workflows. Deployment occurs at the enterprise level, where it integrates into existing clinical and regulatory development processes.

The takeaway

The industry is shifting toward predictive analytics to mitigate the million-dollar costs associated with mid-trial protocol changes. Investors and clinical leads should watch for future reports on cost-savings metrics as the startup scales its commercial relationships.